Spruce Biosciences, Inc. SPRB
We take great care to ensure that the data presented and summarized in this overview for SPRUCE BIOSCIENCES, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding SPRB
View all-
River Vest Venture Management LLC St. Louis, MO2.94MShares$1.15 Million20.39% of portfolio
-
Carlyle Group Inc. Washington, DC2.9MShares$1.13 Million0.2% of portfolio
-
Rock Springs Capital Management LP Baltimore, MD2.61MShares$1.02 Million0.04% of portfolio
-
Abingworth LLP London, X01.79MShares$699,0820.65% of portfolio
-
Acadian Asset Management LLC Boston, MA1.26MShares$491,0680.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA844KShares$329,0990.0% of portfolio
-
Sands Capital Ventures, LLC Arlington, VA787KShares$306,9320.19% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny610KShares$237,7830.0% of portfolio
-
Adar1 Capital Management, LLC Austin, TX404KShares$157,4490.03% of portfolio
-
Almitas Capital LLC Santa Monica, CA397KShares$154,6370.09% of portfolio
Latest Institutional Activity in SPRB
Top Purchases
Top Sells
About SPRB
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was incorporated in 2014 and is headquartered in Daly City, California.
Insider Transactions at SPRB
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 16
2024
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
20,820
-6.44%
|
$0
$0.39 P/Share
|
|
Dec 16
2024
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
58,350
+15.28%
|
-
|
|
Dec 16
2024
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
71,610
-7.65%
|
$0
$0.39 P/Share
|
|
Dec 16
2024
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
200,700
+17.65%
|
-
|
|
Dec 16
2024
|
Samir M. Gharib PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
27,028
-3.84%
|
$0
$0.39 P/Share
|
|
Dec 16
2024
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,750
+9.73%
|
-
|
|
Dec 10
2024
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
37,964
-23.47%
|
$0
$0.54 P/Share
|
|
Dec 10
2024
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
106,400
+39.68%
|
-
|
|
Dec 10
2024
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
128,020
-27.47%
|
$0
$0.54 P/Share
|
|
Dec 10
2024
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
358,800
+43.5%
|
-
|
|
Dec 10
2024
|
Samir M. Gharib PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
54,948
-15.4%
|
$0
$0.54 P/Share
|
|
Dec 10
2024
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
154,000
+30.15%
|
-
|
|
Mar 21
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
465,021
-15.42%
|
$0
$0.75 P/Share
|
|
Mar 20
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
359,979
-10.67%
|
$0
$0.73 P/Share
|
|
Mar 19
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
593,000
-14.94%
|
$0
$0.76 P/Share
|
|
Mar 18
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
842,020
-17.51%
|
$0
$0.77 P/Share
|
|
Mar 14
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,912,316
-28.45%
|
$0
$0.89 P/Share
|
|
Dec 29
2023
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,361
+14.46%
|
$0
$0.98 P/Share
|
|
Dec 29
2023
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+5.26%
|
$0
$0.98 P/Share
|
|
Dec 15
2023
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
38,384
-26.34%
|
$38,384
$1.66 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 20.6K shares |
|---|---|
| Exercise of conversion of derivative security | 954K shares |
| Payment of exercise price or tax liability | 340K shares |
|---|---|
| Open market or private sale | 4.17M shares |